Trials with recombinant growth factor in necrotizing enterocolitis and interstitial cystitis are expected later this year.



Trillium Therapeutics received $12 million from existing investors to advance its lead candidate into clinical development. TTI-1612 is a recombinant growth factor under parallel development for the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis.


TTI-1612 is scheduled to begin clinical testing by the end of 2008, and two additional trials are projected to commence in 2009, Trillium reports.


Trillium has two other preclinical programs, a CD200-specific anticancer mAb and a CD200Fc fusion protein for autoimmune and inflammatory diseases. The company says that it will use some of the funds to bring these compounds into clinical evaluations as well.


The participating investors are VenGrowth Private Equity Partners, BDC Capital, and Canadian Medical Discoveries Fund.








This site uses Akismet to reduce spam. Learn how your comment data is processed.